Page 38 - Revol202
P. 38
Nuevas alternativas psicoterapéuticas para pacientes con Trastorno Límite de Personalidad y síntomas de larga evolución
33. Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, et al. Psilocybin with psychological support for treatment-re-
sistant depression: six-month follow-up. Psychopharmacology. 2018;235(2):399-408. Disponible en: https://doi.org/10.1007/
s00213-017-4771-x
34. Zeifman RJ, Wagner AC. Exploring the case for research on incorporating psychedelics within interventions for borderline persona-
lity disorder. J Contextual Behav Sci. 2020;15:1-11. Disponible en: https://doi.org/10.1016/j.jcbs.2019.11.001.
35. Domínguez-Clavé E, Soler J, Elices M, Pascual JC, Álvarez E, de la Fuente Revenga M, et al. Ayahuasca: pharmacology, neuroscience,
and therapeutic potential. Brain Res Bull. 2016;126(Pt1):89-101. Disponible en: https://doi.org/10.1016/j.brainresbull.2016.03.002.
36. Franquesa A, Sainz-Cort A, Gandy S, Soler J, Alcázar-Córcoles MÁ, Bouso JC. Psychological variables implied in the therapeutic
effect of ayahuasca: a contextual approach. Psychiatry Res. 2018;264:334-339. Disponible en: https://doi.org/10.1016/j.psy-
chres.2018.04.012.
37. Soler J, Elices M, Franquesa A, Barker S, Friedlander P, Feilding A, et al. Exploring the therapeutic potential of Ayahuasca: acute in-
take increases mindfulness-related capacities. Psychopharmacology. 2016;233(5):823-829. Disponible en: https://doi.org/10.1007/
s00213-015-4162-0.
38. Domínguez-Clavé E, Soler J, Pascual JC, Elices M, Franquesa A, Valle M, et al. Ayahuasca improves emotion dysregulation in a com-
munity sample and in individuals with borderline-like traits. Psychopharmacology. 2019;236(2):573-580. Disponible en: https://doi.
org/10.1007/s00213-018-5085-3.
39. Domínguez-Clavé E, Soler J, Elices M, Franquesa A, Álvarez E, Pascual JC. Ayahuasca may help to improve self-compassion and
self-criticism capacities. Hum Psychopharmacol. 2022;37(1):e2807. Disponible en: https://doi.org/10.1002/hup.2807.
40. Quintana DS, Lischke A, Grace S, Scheele D, Ma Y, Becker B. Advances in the field of intranasal oxytocin research: lessons learned
and future directions for clinical research. Mol Psychiatry. 2021;26(1):80-91. Disponible en: https://doi.org/10.1038/s41380-020-
00864-7.
41. Bujanow W. Is oxytocin an anti-schizophrenic hormone? Can Psychiatr Assoc J. 1974;19(3):323. Disponible en: https://doi.
org/10.1177/070674377401900323.
42. Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E. Oxytocin increases trust in humans. Nature. 2005;435(7042):673-676. Dispo-
nible en: https://doi.org/10.1038/nature03701
43. Pérez-Arqueros V, Soler J, Schmidt C, Vega D, Pascual JC. Could intranasal oxytocin enhance the effects of psychotherapy in indivi-
duals with mental disorders? A systematic review and meta-analysis. Psychoneuroendocrinology. 2025;171:107206. Disponible en:
https://doi.org/10.1016/j.psyneuen.2024.107206.
44. Berceanu AI, Papasteri C, Sofonea A, Boldasu R, Nita D, Poalelungi C, et al. Oxytocin predicts positive affect gains in a role-play inte-
raction. Front Psychol. 2024;15:1258254. Disponible en: https://doi.org/10.3389/fpsyg.2024.1258254.
45. Carrasco JL, Buenache E, MacDowell KS, De la Vega I, López-Villatoro JM, Moreno B, et al. Decreased oxytocin plasma levels and oxyto-
cin receptor expression in borderline personality disorder. Acta Psychiatr Scand. 2020;142(4):319-325. doi:10.1111/acps.13222.
46. Galvez-Merlin A, López-Villatoro JM, de la Higuera-González P, de la Torre-Luque A, McDowell K, Díaz-Marsá M, et al. Decreased
oxytocin levels related to social cognition impairment in borderline personality disorder. Acta Psychiatr Scand. 2024 Jun;149(6):458-
466. doi: 10.1111/acps.13679.
47. Bertsch K., Herpertz S. C. Oxytocin and Borderline Personality Disorder. Current Topics in Behavioral Neuroscience. Vol. 35. Berlín:
Springer; 2018.
38 Rehabilitación Psicosocial - Volumen 20 nº 2 - Julio - Diciembre 2024
